Get the Stockscreener App
340.95
2.73%
-9.61
Praxis Precision Medicines Inc stock is traded at $340.95, with a volume of 202.37K.
It is down -2.73% in the last 24 hours and down -2.56% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$350.56
Open:
$340.92
24h Volume:
202.37K
Relative Volume:
0.43
Market Cap:
$9.52B
Revenue:
$7.46M
Net Income/Loss:
$-326.53M
P/E Ratio:
-25.48
EPS:
-13.3803
Net Cash Flow:
$-282.53M
1W Performance:
+11.67%
1M Performance:
-2.56%
6M Performance:
+14.81%
1Y Performance:
+710.94%
1-Day Range:
$324.62
$346.40
1-Week Range:
$302.50
$354.17
52-Week Range:
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
341.41 | 9.14B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
497.83 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.04 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.22 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.97 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.82 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Price to earnings forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines stock falls on FDA review delay By Investing.com - Investing.com India
Praxis Precision Medicines stock falls on FDA review delay - Investing.com UK
FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026 - Stock Titan
Praxis Precision Medicines Announces FDA Extends Review of Relutrigine NDA to December 27, 2026 - Quiver Quantitative
FDA delays Praxis relutrigine review by three months to Dec. 27 - Stock Titan
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
PRAX Maintained by Needham -- Price Target Raised to $575 - GuruFocus
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell 3000E Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell Microcap Index - marketscreener.com
Praxis gains FDA breakthrough therapy status for elsunersen for encephalopathy - MSN
Praxis Precision Medicines director Jill DeSimone sells $3.6m in shares - Investing.com
Praxis Precision Medicines(PRAX.US) Director Sells US$3.61 Million in Common Stock - Moomoo
Form 4 Praxis Precision Medicines Inc For: 26 June By Investing.com - Investing.com Canada
Praxis Precision Medicines Insider Sold Shares Worth $3,611,335, According to a Recent SEC Filing - marketscreener.com
Praxis (PRAX) director logs 11,600-share sale after option exercises - Stock Titan
null - Trefis
Praxis Precision Medicines, Inc. Actuals & Estimates (BOATS:PRAX) - TradingView
Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree - Trefis
PRAX Stock Price, Quote & Chart - ChartMill
Praxis Precision Medicines outlines next steps, shares trade quietly on Nasdaq - Ad-hoc-news.de
PRAX Forecast — Price Target — Prediction for 2027 - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, Quote, News & Analysis - Seeking Alpha
Form 144 Praxis Precision Medicines For: 24 June By Investing.com - Investing.com Australia
[144] Praxis Precision Medicines, Inc. SEC Filing - Stock Titan
Praxis Precision Medicines (PRAX): Best Upside Stocks to Buy According to Hedge Funds - Insider Monkey
Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen (PRAX) - Seeking Alpha
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $550 - Moomoo
5 Best Upside Stocks to Buy According to Hedge Funds - Insider Monkey
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results - Sahm
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen (PRAX-222) in Pediatric SCN2A-DEE Seizures - Minichart
Praxis Precision Medicines stock rises on FDA breakthrough status - Investing.com
FDA grants breakthrough therapy status to Praxis’ elsunersen - Investing.com UK
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants - Investing News Network
Form 8K Praxis Precision Medicines Inc For: 22 June By Investing.com - Investing.com Australia
Praxis Precision Medicines receives FDA breakthrough therapy designation for elsunersen - Investing.com South Africa
FDA Breakthrough Therapy nod for Praxis (PRAX) seizure drug elsunersen - Stock Titan
Praxis Precision Medicines gains after FDA grants breakthrough therapy designation - MSN
Praxis Precision Medicines (PRAX) Receives FDA Breakthrough Ther - GuruFocus
Praxis Precision (PRAX) Receives FDA Breakthrough Designation fo - GuruFocus
Praxis Precision Medicines Potential Epilepsy Treatment Receives US FDA Breakthrough Therapy Designation - Moomoo
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation - Yahoo Finance
Praxis Precision Medicines stock rises on FDA breakthrough status By Investing.com - Investing.com South Africa
FDA gives Praxis seizure drug Breakthrough Therapy status - Stock Titan
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision Medicines (PRAX) Proxy filing Summary - Quartr
Praxis Precision Medicines (PRAX) Q1 2026 earnings summary - Quartr
Praxis Precision Medicines (PRAX) Q4 2025 earnings summary - Quartr
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DeSimone Jill | Director |
Jun 24 '26 |
Sale |
311.32 |
11,600 |
3,611,335 |
2,337 |
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):